Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-31T15:41:15.308Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of carbamazepine on agitation and emotional lability associated with severe dementia

Published online by Cambridge University Press:  16 April 2020

MR Lemke
MR Lemke*
Affiliation:
Department of Psychiatry, Ingolstadt Medical Center, Krumenauerstr 25, D-85049Ingolstadt, Germany
Get access

Summary

In an open prospective study, the stabilizing effects of carbamazepine on agitation, impulsivity and affective lability were investigated in 15 severely demented patients, who had failed to respond to prior neuroleptic medication. Because of leukopenia and allergic reactions in two subjects, carbamazepine treatment was discontinued. In nine patients a clinically relevant improvement was observed.

Keywords

carbamazepineagitationdementiazotepine
Type
Short communication
Information
European Psychiatry , Volume 10 , Issue 5 , 1995 , pp. 259 - 262
Copyright
Copyright © Elsevier, Paris 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ackenheil, MThe biochemical action profile of zotepine compared with that of other neuroleptics Fortschr Neurol Psychiatr 59suppl 11991 2–9CrossRefGoogle Scholar
Ballenger, JCThe clinical use of carbamazepine in affective disorders J Clin Psychiatry 49suppl 41988 13–19Google ScholarPubMed
Dieterle, DM, Ackenheil, M, Müller-Spahn, F, Kapfhammer, HPZotepine, a neuroleptic drug with a bipolar therapeutic profile Pharmacopsychiatry 20suppl 11987 52–58CrossRefGoogle ScholarPubMed
Dose, M, Apelt, S, Emrich, HMCarbamazepine as adjunct of antipsychotic therapy. Psychiatry Res 1987; 2: 23–24Google Scholar
Essa, MCarbamazepine in dementia. J Clin Psychopharmacol 1986; 6: 234–236Google ScholarPubMed
Finzen, ACarbamazepine in the treatment of mania and prevention of relapses in affective disorders. Psychiatr Prax 1991; 18: 1–8Google Scholar
Folstein, M, Folstein, S, McHugh, PRMini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198CrossRefGoogle ScholarPubMed
Gaitz, CM, Varner, RV, Overall, JEPharmacotherapy for organic brain syndrome in late life. Arch Gen Psychiatry 1977; 34: 839–845CrossRefGoogle ScholarPubMed
Gardner, DL, Cowdry, RWPositive effects of carbamazepine on behavioral dyscontrol in borderline personality. Am J Psychiatry 1986; 143: 519–522Google ScholarPubMed
Gleason, RP, Schneider, LSCarbamazepine treatment of agitation in Alzheimer–s outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51: 115–118Google ScholarPubMed
Heath, RGStudies with deep electrodes in patients intractable ill with epilepsy and other disordersTrimble, MR, Reynolds, EHWhat is epilepsy? Edingburgh: Churchill Livingston, 1986; 126–132Google Scholar
Helmchen, H, Kanowski, S, Koch, HGResearch with demented patients: need for research and the problem of informed consent. Ethik Med 1989; 1: 83–98Google Scholar
Jann, MW, Ereshefsky, L, Saklad, SRet al.Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985; 5: 106–109CrossRefGoogle ScholarPubMed
Kane, JM, Smith, JMTardive dyskinesia. Arch Gen Psychiatry 1982; 39: 473–481CrossRefGoogle ScholarPubMed
Lemke, MRTherapeutic effect of carbamazepine on affective liability and agitation associated with dementia Neuropsychopharmacol 9suppl 21993 126Google Scholar
Lemke, MRCarbamazepine treatment of agitated dementia Munch Med Wschr 1994 136Google Scholar
Marin, DB, Greenwald, BSCarbamazepine for aggressive agitation in demented patients during nursing care. Am J Psychiatry 1989; 146: 805Google ScholarPubMed
O–Dougherty, M, Wright, FS, Cox, S, Walson, PCarbamazepine plasma concentration relationship to cognitive impairment. Arch Neurol 1987; 44: 863–867CrossRefGoogle Scholar
Patterson, JFCarbamazepine for assaultive patients with organic brain disease. Psychosomatics 1987; 28: 581–597CrossRefGoogle ScholarPubMed
Post, RMMechanisms of action of carbamazepine and related anti-convulsants in affective illnessMeltzer, HYPsychopharmacology: A Generation of Progress New York: Raven Press, 1987; 567–576Google Scholar
Post, RM, Susan, R, Weiss, BSensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness. Pharmacopsychiat 1992; 25: 41–43CrossRefGoogle ScholarPubMed
Reisberg, B, Borenstein, J, Salob, SPBehavioral symptoms in Alzheimer–s disease: phenomenology and treatment. J Clin Psychiatry 1987; 48: 9–15Google ScholarPubMed
Shader, RI, Harmatz, JS, Salzman, CA new scale for clinical assessment on geriatric populations: Sandoz Clinical Assessment-Geriatric. J Am Geriatr Soc 1974; 22: 107–113CrossRefGoogle ScholarPubMed
Schneider, LS, Pollok, VE, Lyness, SAA metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr 1990; 38: 553–563CrossRefGoogle ScholarPubMed
Siever, L, Trestman, RLThe serotonin system and aggressive personality disorder Int Clin Psychopharmacol 8suppl 21993 33–39CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.